 Expects fourth quarter 2022 preliminary UPNEEQ net product sales of approximately 12.1 million, representing an increase of 21 over the third quarter 2022, and approximately 36.5 million for full year 2022 Approximately 4,300 cumulative unique medical aesthetics practices had placed orders for UPNEEQ through the end of the fourth quarter 2022, a ... The post RVL Pharmaceuticals plc Announces Preliminary Fourth Quarter Sequential Growth of 21 and Full Year 2022 UPNEEQ Net Product Sales... 